Revista de la OFIL
ISSN 1699-714X ISSN 1131-9429
MATEU-PUCHADES, A et al. Effectiveness, safety, quality of life and satisfaction of patients with palmo-plantar psoriasis treated with calcipotriol and betametasone foam. []. , 32, 1, pp.22-28. 21--2022. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2022000100005.
Objective:
To evaluate effectiveness, safety, quality of life and satisfaction of patients with non-pustular palmo-plantar (PP) psoriasis treated with calcipotriol and betamethasone (Cal/BD) foam.
Material and methods:
Observational, prospective study. We included adult patients with a diagnosis of uncontrolled PP psoriasis in which topical treatment was indicated. Demographic (sex and age), anthropometric (body mass index (BMI)), related to the pathology (Body Surface Area (BSA) categorized as <10% or ≥10%) and related to the treatment (previous pharmacological treatments) variables were studied. To evaluate effectiveness and safety of the treatment, Palmoplantar Psoriasis Area Severity Index (PPASI) and Physician’s Global Assessment (PGA) were used, and the incidence and severity of the adverse effects were collected. To assess quality of life, Dermatology Life Quality Index (DLQI) was used, as well as Treatment Satisfaction Questionnaire for Medication (TSQM-14) to assess patient satisfaction with treatment at the 4th week. The variables of effectiveness and quality of life were evaluated at the beginning and at 4th week of treatment, calculating the difference in absolute terms between them.
Results:
We included 19 patients (11 women) with a median of 59 (IQR 11.4) years old and a BMI of 25.9 (IQR 6.0) kg/m2. All the patients showed a BSA <10% and were previously treated with topical treatments (74%; 14/19), acitretin (48%; 9/19) and immunosuppressants (26%; 5/19), among others.
The median reduction in PPASI was 3.6 (IQR 7.8) (p=0.0284), while the median reduction in PGA was 1.0 (IQR 2.0) (p=0.0047). No patient presented adverse reactions related with the medication. The median reduction in DLQI was 3.0 (IQR 4.0) (p=0.1592). The overall satisfaction of the patient was 76.9 (IQR 32.2) over 100.
Conclusion:
Cal/BD foam for topical administration in patients with PP psoriasis shows to be effective and safe, obtaining a good result in terms of overall patient satisfaction with the medication, without obtaining differences in terms of quality of life.
: Psoriasis/drug therapy; treatment outcome; patient reported outcome measures.